The Daily Buyout
$36.50/share cashStrategic acquisitionHealthcare & Life SciencesCompleted

Viatris completes $36.50-a-share takeover of Pacira BioSciences

Viatris has completed its acquisition of non-opioid pain specialist Pacira BioSciences after a $36.50-per-share cash tender offer. About 66.46% of shares were tendered, and Pacira was then merged into a Viatris subsidiary. The deal was first announced on Oct. 8, 2026.

Why it matters: Viatris says the deal gives it a leadership position in non-opioid pain management as it builds out its U.S. innovative medicines business.

Read the full coverage, free

We only link to sources you can read without a subscription. How we check.

Following healthcare M&A?

The next big healthcare deal will be in our email the morning after it's announced, with the rest of the day's biggest deals. Free, with no paywalled links.

Free · Unsubscribe anytime

See what you get →